標(biāo)題: Titlebook: New Developments in Antirheumatic Therapy; K. D. Rainsford,G. P. Velo Book 1989 Kluwer Academic Publishers 1989 Arthritis.drug.drug develo [打印本頁(yè)] 作者: 重婚 時(shí)間: 2025-3-21 16:50
書(shū)目名稱(chēng)New Developments in Antirheumatic Therapy影響因子(影響力)
書(shū)目名稱(chēng)New Developments in Antirheumatic Therapy影響因子(影響力)學(xué)科排名
書(shū)目名稱(chēng)New Developments in Antirheumatic Therapy網(wǎng)絡(luò)公開(kāi)度
書(shū)目名稱(chēng)New Developments in Antirheumatic Therapy網(wǎng)絡(luò)公開(kāi)度學(xué)科排名
書(shū)目名稱(chēng)New Developments in Antirheumatic Therapy被引頻次
書(shū)目名稱(chēng)New Developments in Antirheumatic Therapy被引頻次學(xué)科排名
書(shū)目名稱(chēng)New Developments in Antirheumatic Therapy年度引用
書(shū)目名稱(chēng)New Developments in Antirheumatic Therapy年度引用學(xué)科排名
書(shū)目名稱(chēng)New Developments in Antirheumatic Therapy讀者反饋
書(shū)目名稱(chēng)New Developments in Antirheumatic Therapy讀者反饋學(xué)科排名
作者: 上漲 時(shí)間: 2025-3-21 20:48 作者: 使苦惱 時(shí)間: 2025-3-22 02:52 作者: 著名 時(shí)間: 2025-3-22 08:00 作者: 缺乏 時(shí)間: 2025-3-22 10:33 作者: 賞錢(qián) 時(shí)間: 2025-3-22 16:48 作者: 出來(lái) 時(shí)間: 2025-3-22 17:06 作者: 折磨 時(shí)間: 2025-3-23 00:13 作者: glacial 時(shí)間: 2025-3-23 04:15 作者: 光明正大 時(shí)間: 2025-3-23 07:41 作者: visceral-fat 時(shí)間: 2025-3-23 13:04 作者: 變態(tài) 時(shí)間: 2025-3-23 16:57
K. D. Rainsfordi of intestinal epithelia, peripheral leukocytes, spleen and liver cells, it will be important to study the fate of foreign DNA also in mammalian organisms. The long-term sequelae of this life-long influx of foreign DNA into lite mammalian organism are not known.作者: 重力 時(shí)間: 2025-3-23 20:08
Lisa A. Marshall,Joseph Changhe laboratory..?.Thorough and intuitive,. Transgenic Plants: Methods and Protocols,?Second Edition .aids scientists in the continuous improvements being made for the production and analysis of transgenic plants. .978-1-4939-6078-1978-1-61779-558-9Series ISSN 1064-3745 Series E-ISSN 1940-6029 作者: RACE 時(shí)間: 2025-3-24 02:15
Henry J. Lee,Ann S. Heiman,Irach B. Taraporewalahe laboratory..?.Thorough and intuitive,. Transgenic Plants: Methods and Protocols,?Second Edition .aids scientists in the continuous improvements being made for the production and analysis of transgenic plants. .978-1-4939-6078-1978-1-61779-558-9Series ISSN 1064-3745 Series E-ISSN 1940-6029 作者: amenity 時(shí)間: 2025-3-24 05:12 作者: PATHY 時(shí)間: 2025-3-24 06:59 作者: Herbivorous 時(shí)間: 2025-3-24 10:44 作者: 舊石器時(shí)代 時(shí)間: 2025-3-24 17:29
Michael C. Powanda,Elizabeth D. Moyerhe laboratory..?.Thorough and intuitive,. Transgenic Plants: Methods and Protocols,?Second Edition .aids scientists in the continuous improvements being made for the production and analysis of transgenic plants. .978-1-4939-6078-1978-1-61779-558-9Series ISSN 1064-3745 Series E-ISSN 1940-6029 作者: 調(diào)味品 時(shí)間: 2025-3-24 20:50
Ivan G. Otterness,Marcia L. Blivenhe laboratory..?.Thorough and intuitive,. Transgenic Plants: Methods and Protocols,?Second Edition .aids scientists in the continuous improvements being made for the production and analysis of transgenic plants. .978-1-4939-6078-1978-1-61779-558-9Series ISSN 1064-3745 Series E-ISSN 1940-6029 作者: Munificent 時(shí)間: 2025-3-25 01:49
F. M. Veronese,A. Conforti,G. P. Velohe laboratory..?.Thorough and intuitive,. Transgenic Plants: Methods and Protocols,?Second Edition .aids scientists in the continuous improvements being made for the production and analysis of transgenic plants. .978-1-4939-6078-1978-1-61779-558-9Series ISSN 1064-3745 Series E-ISSN 1940-6029 作者: Chronic 時(shí)間: 2025-3-25 06:00 作者: 抓住他投降 時(shí)間: 2025-3-25 11:28
0923-9405 rheumatoid arth- ritis have given us important indications for the approach employing what are generally described as "immunomodulators" to control this disease978-94-010-7056-0978-94-009-1253-3Series ISSN 0923-9405 作者: 鈍劍 時(shí)間: 2025-3-25 12:50 作者: 吹牛大王 時(shí)間: 2025-3-25 19:49
P. Nash,B. L. Hazlemanall other loci, we predict that such a genotype is far less likely to occur in self-fertile species, where the initial hybrid develops into a series of inbred lines, than in outcrossing species, where the inital hybrid can quickly shed deleterious crop alleles through repeated backcrossing.作者: 豪華 時(shí)間: 2025-3-25 21:04
I. M. Hunneyball,M. E. J. Billingham,K. D. Rainsfordiating their functionality. Data from single strain cultures and some communities demonstrate basic features of the data obtained and some determinants of their variation and inferences on the analysis by multivariate statistics are mentioned.作者: 緊張過(guò)度 時(shí)間: 2025-3-26 00:42
978-94-010-7056-0Kluwer Academic Publishers 1989作者: crescendo 時(shí)間: 2025-3-26 08:21 作者: 巧思 時(shí)間: 2025-3-26 12:27 作者: 收集 時(shí)間: 2025-3-26 16:18
https://doi.org/10.1007/978-94-009-1253-3Arthritis; drug; drug development; inflammation; osteoarthritis; research; rheumatoid arthritis; toxicity作者: conquer 時(shí)間: 2025-3-26 17:29
Do platelet activating factor antagonists have a potential role in the therapy of rheumatoid arthri by an extensive accumulation of inflammatory cells in the synovial lining of joints and tendons. In addition, there is collagen and connective tissue degradation, fibrinoid necrosis and deposition of immune complexes on vascular endothelium generating local inflammation and infarction.作者: intuition 時(shí)間: 2025-3-27 00:37
The T cell as a therapeutic target, an infectious aetiology or a pathognomonic immune abnormality, these diseases are characterized as being autoimmune. Rheumatoid arthritis, systemic lupus erythematosus, myasthenia gravis and multiple sclerosis are all well-known examples. An important therapeutic approach to these diseases is the selective inhibition of immune activity.作者: Glycogen 時(shí)間: 2025-3-27 01:17
Recent developments in antirheumatic therapy,This chapter will discuss recent developments in anti-rheumatic therapy and serve as an introduction to later chapters in which a variety of novel therapeutic approaches will be discussed in more detail, including topics from newer avenues of immunomodulation to alternative methods of drug delivery.作者: 柔軟 時(shí)間: 2025-3-27 09:15
Gold(I)-thiolates: slow-acting anti-arthritic drugs,Chrysotherapy, the current use of gold-containing drugs to treat rheumatoid disease, presents many problems — some intriguing, others quite vexing:作者: Iniquitous 時(shí)間: 2025-3-27 12:21
Superoxide dismutase modifications for anti-inflammatory therapy,In the early 1960s a metalloprotein with anti-inflammatory properties in man and animals was isolated from bovine liver., which was, some years later identified as superoxide dismutase (SOD). This is a copper-zinc protein which has subsequently been purified and characterized by McCord and Fridovich..作者: 伸展 時(shí)間: 2025-3-27 16:43 作者: 生命層 時(shí)間: 2025-3-27 18:37 作者: MAG 時(shí)間: 2025-3-27 22:43
Animal models of arthritic disease: influence of novel compared with classical antirheumatic agentsthese crippling afflictions. Unfortunately this is not yet totally so, and our existing models of arthritis are frequently criticized for both their failure to replicate the human condition, and to reliably demonstrate the disease-modifying qualities of gold and penicillamine, the mainstays of human作者: 果仁 時(shí)間: 2025-3-28 04:28
Novel eicosanoid inhibitors,ver 50 years ago. We now know that AA can be transformed into not just prostaglandins (PGs) and thromboxanes (TxB.) but also 5-lipoxygenase (5-LO) products collectively termed leukotrienes (LTs). Whether all the metabolites of AA have been identified is uncertain and the recent discovery of lipoxins作者: Thymus 時(shí)間: 2025-3-28 07:14
New steroidal anti-inflammatory drugs,pment of local corticosteroids. Two synthetic approaches have been dominant: a traditional means of increasing lipophilicity of potent corticosteroids by masking the hydroxyl group and synthesis of non-systemic steroids by introducing metabolically labile functional groups. The slow increase in the 作者: 哀悼 時(shí)間: 2025-3-28 13:14 作者: nonradioactive 時(shí)間: 2025-3-28 14:58 作者: medium 時(shí)間: 2025-3-28 21:34
Interleukin 1: past, present, future,1) can be assigned conveniently to one of three phases: past, present and future. We suggest, however, the key discriminant in the transition from one phase to another is not so much a discrete moment in time, but rather a shift in perspective, which has a temporal component. Thus we have chosen to 作者: 進(jìn)步 時(shí)間: 2025-3-29 00:52 作者: Thymus 時(shí)間: 2025-3-29 06:38 作者: 難聽(tīng)的聲音 時(shí)間: 2025-3-29 10:31 作者: FLAGR 時(shí)間: 2025-3-29 14:15 作者: NUDGE 時(shí)間: 2025-3-29 17:22 作者: 隱語(yǔ) 時(shí)間: 2025-3-29 20:42
